FYN公司
化学
激酶
葛兰素史克-3
药理学
生物化学
原癌基因酪氨酸蛋白激酶Src
医学
作者
Giambattista Marotta,Francesca Massenzio,José Antonio Ortega,Debora Russo,Ilaria Penna,Federico Falchi,Giorgia Babini,Sabrina Petralla,Rita Scarpelli,Elena Roggiolani,Gert Fricker,Michela Rosini,Andrea Cavalli,Barbara Monti,Anna Minarini,Filippo Basagni
出处
期刊:PubMed
日期:2025-08-08
标识
DOI:10.1021/acs.jmedchem.5c00629
摘要
The lack of efficient treatments and reliable biomarkers for neurodegenerative diseases requires the development of a late-stage powerful therapy. To this aim, we focused on Fyn and GSK-3β because both kinases are strictly involved in regulating neurodevelopmental processes, besides orchestrating neurotoxic aggregates' deposition and neuroinflammatory processes development. Based on these premises, we developed dual kinase inhibitors to verify at the cellular level the suitability of Fyn and GSK-3β modulation in pursuing the recovery of neural trophism paired to the activation of a neuroprotective profile. Starting from the mild inhibitory potency of the 3-aminothiazole-7-azaindole scaffold, we identified nanomolar dual and selective inhibitors among the kinases of interest. In-depth biological evaluations were performed with the best compounds of the series to assess the neuroprotective and neuromodulatory properties, like enabling neurogenesis or glial polarization, as well as triggering immunomodulation with different patterns relating to their inhibitory profile, setting the stage for potential development of neuroregenerative treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI